Platform Fertility has the top reproductive healthcare resources in the U.S. You can make free appointments with clinics and doctors based on your treatment needs!
1. Authoritative data in the field of reproduction, top of the list in the number of IVF cycles, and the best live birth rate results.
According to the International Monitoring Committee on Assisted Reproductive Technology (ICMART), 79 countries around the world China, Japan, and the United States rank in the top three for the number of ART cycles, with the U.S. topping the list with a single live birth rate. SART/CDC (Society for Assisted Reproductive Technology/CDC) data shows that 453 clinics across the country reported 413,000+ ART cycles in 2021. We will match you with the clinic on the list of the most suitable clinics for you with high live birth rates based on your age, ovarian condition and treatment needs.
2. A global leader in fertility science, research and treatment, bringing together a wide range of scientists, researchers and reproductive endocrinologists. .
Our practice is recognized by the reproductive industry and the media as a leader, and a global leader, and in addition to board-certified OB/GYNs, reproductive endocrinologists, and infertility specialists, we have a large number of Top Doctors in the field of infertility (the top doctors in their specialties (fewer than 5%) are selected as Top Doctors), reproductive medicine textbook authors, Harvard Medical School Clinical Professors, Lecturers, and one of the nation’s few reproductive endocrinologists trained in embryology.
State-of-the-art laboratories, passionate and skilled embryologists, scientists, and physicians with a relentless focus on discovery, and then turning ideas into science and science into success, this spirit of research and innovation has made it possible for IVF to advance by leaps and bounds, bringing new standards of care and benchmarks of success to the industry, and contributing to the success of more families.
3. Leading laboratory and blastocyst culture technology The The environment, technology, equipment, and especially the expertise of the embryologist in the IVF laboratory are important factors in the development of high quality embryos.
Embryologists, usually categorized as Junior Embryologists, Senior Embryologists, and IVF Laboratory Directors. They work to ensure that the laboratory is an ideal environment for the growth and storage of embryos. An example is Clinic A:
3.1 Air: A customized air purification system is used in the laboratory to ensure the highest air quality and strict environmental controls to optimize embryo development. The purification system not only filters out particulate matter but also controls harmful volatiles.
3.2 Temperature, humidity and gases: The laboratory mimics the stable reproductive environment in which embryos thrive in females, minimizing environmental changes to avoid stressing the embryo and interfering with its development.
3.3 Quality Control: The clinic has implemented an additional level of quality control testing on all manufacturer-developed media and contacts. This additional testing requires the use of an ultrasensitive bioassay to ensure that the media and contacts are not toxic to the developing embryo.
3.4 Incubation Techniques: When observing or handling embryos under a microscope, they are removed from the incubator in many laboratories and simply placed on a heated surface in a room atmosphere. Clinic A’s mobile incubator allows embryologists to perform most of these tasks in a regulated and stable environment.
3.5 Day 7 Biopsy: Many laboratories will not culture embryos after Day 5 or Day 6 because the process is both labor intensive and requires additional supplies and expense. Clinic A performs biopsies on Day 7 to ensure that the patient has as many embryos as possible available for biopsy.
3.6 Second day ICSI technique: Intracytoplasmic single sperm injection (ICSI) involves the injection of sperm directly into the egg. Typically, the eggs are retrieved and ICSI is performed on mature eggs later the same day; however, sometimes the eggs take more time to mature and many laboratories do not perform second-day ICSI because it is labor-intensive and involves additional supplies and costs, and they are not confident that it will produce high-quality embryos.
4.Preimplantation genetic testingPGT::Addressing chromosomal abnormalities in older births(math.) genusInterrupting Family Hereditary Diseases(math.) genusEffective reduction of abortion rates(math.) genusand a significant increase in the live birth rateThe
PGT consists of preimplantation genetic testing for PGT-A aneuploidy, PGT-M mono/mono defects, and PGT-SR chromosomal structural rearrangements. 50-70% of miscarriages have been shown to be caused by chromosomal imbalances (too few or too many chromosomes) in the embryo, and a study by the American Society for Reproductive Medicine ASRM showed that women with three normal chromosomes have a 9.9% chance of getting pregnant. A study by the American Society for Reproductive Medicine ASRM showed that women with three normal chromosomes have a 94.9% chance of getting pregnant.
Preimplantation Genetic Testing (PGT), also known as third generation IVF technology, refers to the method of preventing the transmission of genetic diseases by taking the genetic material of embryos for analysis, diagnosing any abnormality, and screening healthy embryos for transfer prior to embryo transfer in IVF-ET. Under normal circumstances, patients only need to undergo PGT-A testing on blastocysts, and other tests on blastocysts are only required if the couple has a family genetic history or Genetic Carrier Screening abnormalities.
| PGT consists of three technologies | Corresponding to the original name | |
|
1. Pre-implantation genetic testing for aneuploidy PGT-A |
The most common chromosomal problem in preimplantation embryos. When an embryo has an incorrect number of chromosomes (gained or lost), it can lead to transfer failure, miscarriage, or chromosomal disorders such as Down syndrome (extra copies of chromosome 21). |
PGS. The probability of aneuploid embryos increases with the age of the woman. 75% of women’s eggs are chromosomally normal at 25 years of age, about 50% at 35 years of age, and about 10-15% at 40 years of age. |
|
2. Pre-implantation genetic testing for monogenic/monogenic defects (PGT-M) |
GT-M was first developed in the early 1990s to screen embryos for X-linked disorders such as fragile X chromosomes. The technique has been refined to include any inherited genetic disease with a known mutation, such as cystic fibrosis, Tay-Sachs disease, muscular dystrophy dystrophy, and more recently, hereditary cancers. Depending on the parents, they have a 25 %或50% chance of being passed on to the embryo. |
PGD Detection of structurally abnormal parts of embryonic chromosomes. |
|
3. Pre-implantation genetic testing for chromosomal structural rearrangements (PGT-SR) |
Suitable for couples in which one of the partners has a chromosomal rearrangement, such as a translocation or inversion, the test looks for any unbalanced form of these rearrangements, thereby reducing the chances of miscarriage and the chances of having a child with a chromosomal abnormality. | |
4.1 Chromosome is the genetic material, the carrier of genes, is a small structure containing tens of thousands of human genes, the genes support the basic structure and performance of life, is an intrinsic factor in determining the health of life, the organism’s birth, growth, decline, old age, disease, death, and so on all the phenomena of life are associated with genes. Each cell of the human body requires a total of 46 chromosomes, initially 23 chromosomes from the egg and 23 chromosomes from the sperm (22 pairs are common to both sexes, and the other pair X/Y is for boys and XX is for girls). Both chromosomes and genes play a vital role in the conception process and can affect the health of the baby; when chromosomal abnormalities or gene mutations occur, they can lead to infertility, miscarriage, or the birth of a child with a genetic disease.
4.2 Detection methods and techniques: 3-8 TE cells of blastocysts (the part that will grow into placenta in the future) were taken from 5-7 days after fertilization, and the DNA was extracted and increased for analysis; the number and structure of chromosomes were compared and analyzed by PGT-A using the Next Generation Sequencing (NGS) technology after DNA was extracted and increased. NGS is a new generation of PGT-A (PGS has three generations of FISH→ACGH→NGS), which is highly accurate and informative, and can screen for small chromosomal micro-deletions and help obtain healthy blastocysts.
4.3 Genetic Diseases: diseases that can be dealt with such as . Brain Cancer, Breast Cancer, Colon Cancer, Endocrine Cancer, Stomach Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecological Tumor, Hematologic Tumor, Melanoma, Ovarian/Tubal Cancer, Pancreatic Cancer, Pediatric Cancer, Prostate Cancer, Skin Cancer, Uterine Cancer, etc. Some of the diseases that have been corresponded to are as follows:
| Duchenne muscular dystrophy | Osteogenesis imperfecta | Osteogenesis imperfecta type II |
| Becker muscular dystrophy | Marfan syndrome | Adult-onset osteogenesis imperfecta |
| Fukuyama-type congenital muscular dystrophy | Recessive hereditary deafness due to mutations in the GJB2 gene | Restrictive Skin Disease |
| Fukuyama-type muscular dystrophy | Autosomal dominant cerebral arteriopathy with subcortical infarcts and white matter encephalopathy | Ornithine carbamyltransferase deficiency |
| Myotonic (Tonic) Dystrophy | Peroneal muscular dystrophy | PDHC deficiency (pyruvate dehydrogenase complex deficiency) (hyperlactate hyperbilirubinemia)) |
| Spinocerebellar degeneration | Perinatal-type hypophosphatasia | 5,10-Methylenetetrahydrofolate reductase deficiency |
| Joubert’s syndrome | Chondrodysplasia | Lesch-Nyhan Syndrome (Self-Destructive Disorder) |
| Huntington’s disease | OTC deficiency | Glutaric acidemia type II |
| Adrenoleukodystrophy | Fabry’s disease | X-linked hereditary hydrocephalus |
| Mucopolysaccharide Storage Disease Type II | Leigh’s Disease | Hematologic Immunity |
| Congenital Ichthyosis | Spinal Muscular Atrophy | Malformation Syndrome |
| Neurofibromatosis type I | Peyme disease | Olbricht’s Syndrome |
| Retinoblastoma | Congenital myopathy |
5. More treatment options
Includes and is not limited to older births, ovulation disorders, egg freezing (fertility preservation), sac freezing, transfer of embryos/gametes (sperm or egg), uterine infertility, preimplantation genetic testing (PGT), familial genetic disorders, recurrent miscarriage, . Male Infertility, Single Parent Legal Childbirth, Same Sex Legal Childbirth (LGBQ Families, etc.), Male AIDS Safe Childbirth (Sperm Washing), Polycystic Ovary Syndrome, Endometriosis, Tubal Reopening, etc.
